ABL Bio’s Partner Compass Therapeutics’ Cholangiocarcinoma Drug Toveximig Receives FDA Orphan Drug Designation
On April 8, ABL Bio, a company specializing in bispecific antibodies, announced that Toveximig, a cholangiocarcinoma treatment being developed by its global partner Compass Therapeutics, has been designated as an orphan drug by the U.S. Food and Drug Administration (FDA).
The orphan drug designation system targets rare diseases affecting fewer than 200,000 patients and is designed to encourage the development of treatments in areas with limited drug development. Once designated as an orphan drug, the product is granted a period of market exclusivity in the United States (typically seven years), along with benefits such as tax credits, partial exemption from FDA review fees, clinical trial grants, and regulatory development support.
Toveximig is a bispecific antibody developed by ABL Bio and licensed to Compass Therapeutics. It works by simultaneously blocking the DLL4 (Delta-like ligand 4) and VEGF-A (Vascular Endothelial Growth Factor-A) signaling pathways, both of which play crucial roles in neovascularization and tumor angiogenesis. According to preclinical and clinical studies, simultaneous inhibition of DLL4 and VEGF-A suppresses tumor cell growth, resulting in strong anticancer effects.
Currently, Compass Therapeutics is conducting the COMPANION-002 phase 2/3 clinical trial in combination with the chemotherapy agent paclitaxel for patients receiving second-line treatment for cholangiocarcinoma. This month, data will be released on key indicators such as overall survival (OS) and progression-free survival (PFS), which have the most significant impact on the FDA’s new drug approval review.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
ABL Bio CEO Sanghoon Lee stated, “In April 2024, Compass Therapeutics already received Fast Track Designation from the FDA for Toveximig and has utilized the benefits of the system for its clinical development. Based on the clinical data from COMPANION-002, Compass Therapeutics plans to discuss the next stages of development with the FDA. We expect that this orphan drug designation, following the Fast Track Designation, will have a positive impact on the approval process for Toveximig.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.